Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
To evaluate the efficacy and safety of apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who failed prior platinum based chemotherapy
Nasopharyngeal Carcinoma
DRUG: Apatinib
CBR(Clinical Benefit Rate), The sum rate of complete response, partial response and stable disease, 12 weeks|The incidence of Grade 3-4 adverse events, Number of participants with adverse events and serious adverse events.In addition,estimating their relationship with apatinib., 2 years
PFS (progression free survival), from the first day of therapy to the date of disease progression or death from any cause, whichever was first (according the criterion of RECIST 1.1 )., 2 years|OS (overall survival), from the first day of therapy to death or last follow-up, 2 years|QoL(quality of life), Changes in quality of life were assessed by EORTC QLQ-C30, 2 years
To evaluate the efficacy and safety of apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who failed prior platinum based chemotherapy